Episurf Medical Q2: Total focus on the US - Redeye

Redeye provides a more in-depth review of Episurf Medical’s Q2 report. Since the company’s sales came in lower than expected, we made some downward adjustments to our estimates for the short and medium-term sales forecasts. We revise our base case valuation to SEK1.3 (SEK1.4) per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/1021947/episurf-medical-q2-total-focus-on-the-us?utm_source=finwire&utm_medium=RSS